Status:

RECRUITING

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Lead Sponsor:

Kamau Therapeutics

Conditions:

Sickle Cell Disease

Eligibility:

All Genders

12-40 years

Phase:

PHASE1

PHASE2

Brief Summary

This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate sa...

Detailed Description

Participants diagnosed with severe SCD will receive nula-cel via IV infusion following myeloablative conditioning in an autologous HSCT setting.

Eligibility Criteria

Inclusion

  • ≥12 to ≤ 40 years
  • Severe disease, as defined by having experienced at least one of the following SCD-related events despite appropriate supportive care measures:
  • recurrent severe VOC (≥ 4 episodes in the preceding 2 years)
  • ACS (≥ 2 episodes in the prior 2 years with at least one episode in the past year)
  • Lansky/Karnofsky performance status of ≥ 80

Exclusion

  • Available 10/10 HLA-matched sibling donor
  • Prior HSCT or gene therapy
  • Prior or current malignancy or myeloproliferative or a significant coagulation or immunodeficiency disorder
  • Clinically significant and active bacterial, viral, fungal or parasitic infection
  • Pregnancy or breastfeeding in a postpartum female
  • Presence of a chromosomal abnormality/mutation that may put the participant at an increased risk for MDS or AML per investigator's judgment

Key Trial Info

Start Date :

November 15 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2028

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04819841

Start Date

November 15 2021

End Date

December 31 2028

Last Update

November 21 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

2

Lucile Packard Children's Hospital

Palo Alto, California, United States, 94304

3

Washington University

St Louis, Missouri, United States, 63110

4

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease | DecenTrialz